TP53 and acute myeloid leukemia: p53 immunohistochemistry (IHC) has been validated as a rapid, cost-effective tool for identifying impactful TP53 mutations in AML, with a proposed 7.2% cutoff for p53-high as a key indicator, utilizing digital image analysis.